The AMPK–mTOR Pathway Is Inhibited by Chaihu Shugan Powder, Which Relieves Nonalcoholic Steatohepatitis by Suppressing Autophagic Ferroptosis by Zheng Liang, Dajin Pi, Jianwei Zhen, Haizhen Yan, Chuiyang Zheng, July Liang Chen, Wen Fan, Qingliang Song, Jinyue Pan, Dongdong Liu, Maoxing Pan, Qinhe Yang, Yupei Zhang

“…Nonalcoholic steatohepatitis (NASH) is the advanced stage of nonalcoholic fatty liver disease (NAFLD), which is distinguished by the accumulation of fat in the liver, damage to liver cells, and inflammation. …”
Get full text

The use of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for diagnosis of hepato-renal syndrome in advanced cirrhotic patients by Mohamed Adel Abd Elaziz, Asmaa Mustafa Gouda Elewa, Dina Zaki Mohamed Zaki Abdel Hamid, Nohier Essam Soliman Ahmed Hassan, Éva Csongrádi, Emad Hamdy Hamouda Mohammed, Mohammed Abdel Gawad

“…Background Chronic liver disease is a common and important clinical problem. …”
Get full text

The Effect of Mesenchymal Stem Cell-Derived Exosomes and miR17-5p Inhibitor on Multicellular Liver Fibrosis Microtissues by Farnaz Sani, Mina Soufi Zomorrod, Negar Azarpira, Masoud Soleimani

“…Although several studies have been conducted on modeling human liver disease, it is still challenging to mimic nonalcoholic fatty liver disease in vitro. …”
Get full text

What are the lived healthcare experiences of patients with primary sclerosing cholangitis? A community-based qualitative interview study by Sheila Greenfield, Gideon Hirschfield, Jayne Parry, Katherine Arndtz, Madeline Cameron

Get full text

Unraveling the Beneficial Role of Resveratrol in Fructose-Induced Non-Alcoholic Steatohepatitis with a Focus on the AMPK/Nrf2 Signaling Axis by Soha S. Zakaria, Safaa M. Hanafy

“…<i>Background and Objectives</i>: High fructose intake is associated with non-alcoholic fatty liver disease (NAFLD), a chronic liver disease that is on the rise worldwide. …”
Get full text

Management of Hepatic Encephalopathy by G. Wright, A. Chattree, R. Jalan

“…Hepatic encephalopathy (HE), the neuropsychiatric presentation of liver disease, is associated with high morbidity and mortality. …”
Get full text

Vibrio vulnificus Septicemia after Handling Tilapia Species Fish: A Canadian Case Report and Review by Donald C Vinh, Samira Mubareka, Bunmi Fatoye, Pierre Plourde, Pamela Orr

“…Primary septicemia is often fatal, principally affecting persons with chronic liver disease.…”
Get full text

Cholestasis in Crohn's Disease: A Diagnostic Challenge by Nir Hilzenrat, Esther Lamoureux, Averell Sherker, Albert Cohen

“…A 24-year-old male with Crohn's disease who developed three independent episodes of cholestatic liver disease over an eight-year period is described. …”
Get full text

Disease Burden of Chronic Hepatitis B among Immigrants in Canada by William WL Wong, Gloria Woo, E Jenny Heathcote, Murray Krahn

“…BACKGROUND: The prevalence of chronic hepatitis B (CHB) infection among immigrants to North America ranges from 2% to 15%, 40% of whom develop advanced liver disease. Screening for hepatitis B surface antigen is not recommended for immigrants.…”
Get full text

Marijuana Use in Hepatitis C Infection does not Affect Liver Biopsy Histology or Treatment Outcomes by Theresa Liu, Glen T Howell, Lucy Turner, Kimberley Corace, Gary Garber, Curtis Cooper

“…The literature assessing the influence of marijuana on liver disease progression and hepatitis C virus antiviral treatment outcomes is conflicting.…”
Get full text

Hyperbilirubinemia: Does It Matter? by Lajos Okolicsanyi, Giulia Martina Cavestro, Claudia Guatti-Zuliani

“…Serum bilirubin concentrations are increased in several hematological and hepatic disorders; however, hyperbilirubinemia, often of familial origin, may occur without overt signs of hemolysis or evident liver disease. The authors review briefly the main steps of hepatic bilirubin metabolism, then discuss the pathogenetic mechanisms of the different forms of familial hyperbilirubinemia. …”
Get full text

Renal Impairment in Cirrhosis Unrelated to Hepatorenal Syndrome by Gavin Low, Graeme JM Alexander, David J Lomas

“…Renal impairment is common in liver disease and may occur as a consequence of the pathophysiological changes that underpin cirrhosis or secondary to a pre-existing unrelated insult. …”
Get full text

Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma by Hideo Suzuki, Motoyuki Kohjima, Masatake Tanaka, Takeshi Goya, Shinji Itoh, Tomoharu Yoshizumi, Masaki Mori, Mariko Tsuda, Motoi Takahashi, Miho Kurokawa, Koji Imoto, Shigeki Tashiro, Akifumi Kuwano, Masaki Kato, Seiji Okada, Makoto Nakamuta, Yoshihiro Ogawa

“…Same metabolic alterations were observed in noncancer tissue as the liver disease progresses from healthy liver to chronic hepatitis, cirrhosis, and HCC. …”
Get full text

Evaluating the therapeutic effect of different forms of silymarin on liver status and expression of some genes involved in fat metabolism, antioxidants and anti‐inflammatory in old... by Samira Faryadi, Ardashir Sheikhahmadi, Ayoub Farhadi, Himan Nourbakhsh

“…Conclusions Overall, the effects of silymarin when converted to NSM or LSM and offered at the level of 200 mg/kg BW were more pronounced on the hepatic variables and may be useful in the prevention of the liver disease in older laying hens.…”
Get full text

RIPK3-Mediated Necroptosis and Neutrophil Infiltration Are Associated with Poor Prognosis in Patients with Alcoholic Cirrhosis by Zhenzhen Zhang, Guomin Xie, Li Liang, Hui Liu, Jing Pan, Hao Cheng, Hua Wang, Aijuan Qu, Yan Wang

“…Alcoholic cirrhosis is an end-stage liver disease with impaired survival and often requires liver transplantation. …”
Get full text

Gambaran NAFLD pada Pasien dengan Sindrom Metabolik di Poliklinik Penyakit Dalam RSUP Dr. M. Djamil Padang by Nadila Andam Astari, Eva Decroli, Eti Yerizel

“…Non alcoholic fatty liver disease (NAFLD) is one of the manifestations of metabolic syndrome. …”
Get full text

Effect of gut microbiota changes on cytokines IL-10 and IL-17 levels in liver transplantation patients by Mohamed Abdel-Raoof Fouda, Mohamed Abdel-Wahhab, Ahmed Esmail Abdelkader, Mohsen El-Sayd Ibrahim, Taher Abozeid Elsheikh, Hisham Mohammad Aldeweik, Nora Elfeky

“…Abstract Background Liver transplantation (LT) is a critical intervention for individuals with end-stage liver disease; yet, post-transplant problems, especially infections, graft rejection, and chronic liver disease, are often linked to systemic inflammation. …”
Get full text

Does Anemia Have a Potential Effect on Type 2 Hepatorenal Syndrome? by Sondes Bizid, Haythem Yacoub, Ghanem Mohamed, Bahaa Ben Slimane, Khouloud Boughoula, Hatem Ben Abdallah, Riadh Bouali, Nabil Abedelli

“…Models of end-stage liver disease (MELD) and Child–Turcotte–Pugh (CTP) scores were calculated. …”
Get full text

Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies by Elisa Monti, Clara Vianello, Ilaria Leoni, Giuseppe Galvani, Annalisa Lippolis, Federica D’Amico, Sara Roggiani, Claudio Stefanelli, Silvia Turroni, Francesca Fornari

“…Hepatocellular carcinoma (HCC) is a heterogeneous tumor associated with several risk factors, with non-alcoholic fatty liver disease (NAFLD) emerging as an important cause of liver tumorigenesis. …”
Get full text

Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan by Selena M. Sagan, Benoit Dupont, Jason Grebely, Mel Krajden, Sonya A. MacParland, Jennifer F. Raven, Sahar Saeed, Jordan J. Feld, D. Lorne Tyrrell, Joyce A. Wilson

“…The Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority. In 2015, the release of well-tolerated, short course treatments (~12 weeks) able to cure the majority of treated HCV patients revolutionized HCV therapy. …”
Get full text